Sector News

Struggling Perrigo OKs plan to hive off prescription business

August 10, 2018
Life sciences

It was nearly two years ago that activist investors began urging Perrigo to hive off its specialty pharma unit. Now, it’s finally happening.

The Dublin drugmaker said Thursday that its board had OK’d a plan to split off the company’s prescription drugs business. It’s a move Perrigo’s directors think will allow the company to “focus on expanding its leading consumer business,” and all options are on the table, including a “tax-efficient separation to shareholders,” a sale or a merger.

The decision follows a strategic review from Perrigo’s board—and considering that board’s makeup, the decision to jettison the prescription business is no surprise. Last February, Perrigo forked over five spots on the company’s boardroom roster to activist Starboard Value, which began publicly lobbying for a split back in September 2016.

“We believe the company could benefit from outside advice from a reputable investment bank or advisor on non-core asset divestitures or other broader strategic alternatives,” Starboard CEO Jeffrey Smith—who now holds one of Perrigo’s board seats—wrote in a letter at the time.

While the board may be gung-ho about the new plan, though, analysts aren’t so sure it’s the right way to go. “The company has been actively discussing this potential separation for some time and the lack of a buyer thus far to us suggests this won’t be easy,” RBC Capital Markets’ Randall Stanicky wrote to clients, adding, “we do not think it is understood how dilutive this is likely to be.”

It’s been a rough two-plus years for Perrigo, featuring two CEO departures, the activist upheaval, layoffs, guidance cuts, a shareholder lawsuit and more. The situation didn’t look much better Thursday, with all three of the company’s units—prescription drugs, generics and OTC—missing consensus expectations.

The prescription segment in particular was hit hard, forcing the company to revise its sales expectations downward and adjust its earnings guidance, too.

By: Carly Helfand

Source: Fierce Pharma

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach